AOD-9604 Medicare Advantage Coverage: What You Need to Know in 2026

Why Medicare Advantage Does Not Cover AOD-9604

Medicare Advantage (MA) prescription drug plans follow the same formulary rules as standalone Medicare Part D. The Centers for Medicare & Medicaid Services (CMS) requires that Part D formularies include only drugs approved by the FDA or, in narrow cases, drugs used in FDA-approved compounding under Section 503B outsourcing facilities for medically necessary treatments. AOD-9604 meets neither criterion.

The peptide has no New Drug Application (NDA) on file. It has no Biologics License Application (BLA). Without these regulatory milestones, CMS formulary inclusion is impossible. This applies uniformly across every Medicare Advantage plan, whether offered by UnitedHealthcare, Humana, Aetna, Cigna, or any regional carrier.

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that was originally investigated by Metabolic Pharmaceuticals in Australia. A Phase IIb trial published in 2004 enrolled 300 obese subjects and found modest weight reduction over 12 weeks, but the company discontinued development before Phase III [1]. No subsequent sponsor has pursued FDA approval. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity does not mention AOD-9604 in its list of recommended agents, reflecting the peptide's lack of regulatory standing.

The FDA Approval Gap and What It Means for Insurance

Every insurance pathway starts with the same question: is the drug FDA-approved? AOD-9604's answer is no. That single fact eliminates coverage from Medicare Part A, Part B, Part D, Medicare Advantage, Medigap supplements, and the vast majority of commercial insurance plans.

The FDA has taken an increasingly active role in peptide regulation since 2023. In November 2023, the agency added several peptides to the FDA's bulk drug substances list with updated conditions for compounding. AOD-9604 is available through 503A compounding pharmacies under the traditional compounding exemption (patient-specific prescriptions), but 503A-compounded products are not eligible for Part D reimbursement. A 503B outsourcing facility could theoretically compound AOD-9604 for office use, but without an FDA-approved reference product, insurers still will not reimburse.

This gap is not unique to AOD-9604. Other peptides like BPC-157 and GHK-Cu face the same exclusion [2]. The distinction matters: FDA-approved semaglutide (Wegovy) gained Medicare Part D coverage for cardiovascular risk reduction after the SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events [3]. AOD-9604 has no comparable outcomes data.

What AOD-9604 Actually Costs Out of Pocket

Without insurance, AOD-9604 is paid entirely in cash. Good news: it is one of the less expensive peptides on the compounding market.

Typical pricing from 503A compounding pharmacies ranges from $150 to $250 for a 30-day supply at standard dosing (250 to 500 mcg per day). Prices vary by pharmacy, geographic region, and whether the peptide is supplied as a lyophilized vial requiring reconstitution or a pre-mixed injectable.

A breakdown of cost factors:

• Peptide vial (5 mg lyophilized): $80 to $150 per vial, typically lasting 10 to 20 days depending on dose
• Bacteriostatic water: $5 to $15 per vial
• Insulin syringes: $10 to $20 per box of 100
• Prescriber consultation: $50 to $200 for initial telehealth visit; some clinics bundle this into monthly membership fees
• Follow-up visits: $0 to $75 per month depending on provider model

Some telehealth platforms offer bundled peptide programs that include the prescription, the compounded peptide, supplies, and provider oversight for $199 to $349 per month. These programs simplify access but may cost more than sourcing each component separately.

How to Reduce Your AOD-9604 Costs

Price shopping is the single most effective strategy. Compounding pharmacy pricing is not standardized, and markups vary widely.

Compare at least three 503A pharmacies. Request quotes for the same formulation (concentration, volume, peptide source) so you are comparing equivalent products. Pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or verified by state boards offer more reliable quality control. Ask specifically about third-party purity testing; reputable pharmacies will share certificates of analysis.

Buy in larger quantities. Many compounding pharmacies offer a 10% to 20% discount for 60- or 90-day supplies. A 90-day order at $400 versus three monthly orders at $180 each ($540 total) saves $140 per quarter.

Use a telehealth provider with pharmacy partnerships. Telehealth platforms negotiate volume discounts with compounding pharmacies. Monthly membership models ($149 to $249) often undercut the combined cost of an independent prescriber plus separate pharmacy order.

Ask about peptide stacking discounts. Patients using multiple peptides (for example, AOD-9604 plus CJC-1295/Ipamorelin) may receive bundled pricing. Some pharmacies discount the second or third peptide by 15% to 25%.

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). AOD-9604, when prescribed by a licensed provider for a diagnosed medical condition, may qualify as an eligible medical expense under IRS rules. The IRS Publication 502 defines eligible expenses as costs for the "diagnosis, cure, mitigation, treatment, or prevention of disease." Consult a tax professional before assuming eligibility, as enforcement varies.

There is no manufacturer coupon for AOD-9604. Because the peptide is compounded rather than manufactured by a single pharmaceutical company, traditional coupon or copay card programs do not exist. Discount programs like GoodRx, SingleCare, and RxSaver do not list compounded peptides.

Clinical Evidence Behind AOD-9604

Understanding the evidence helps contextualize why insurers have not moved toward coverage, and why FDA approval remains distant.

The most cited study is the Metabolic Pharmaceuticals Phase IIb trial from 2004. In this randomized, double-blind, placebo-controlled trial of 300 obese adults (BMI 35 to 45), participants received oral AOD-9604 at doses of 1 mg, 5 mg, 10 mg, 20 mg, or placebo daily for 12 weeks. The 1 mg group lost 2.8 kg versus 1.5 kg for placebo, a statistically significant but clinically modest difference [1]. Higher doses did not show a clear dose-response relationship, and the trial was not powered for long-term outcomes.

Preclinical data from the Obesity Research journal (now Obesity) showed that AOD-9604 stimulated lipolysis in adipose tissue without the diabetogenic or growth-promoting effects of full-length HGH [4]. A 2001 study in obese Zucker rats demonstrated reduced body fat without changes in IGF-1 levels, fasting glucose, or insulin sensitivity. These properties made the peptide attractive for metabolic research but were never confirmed in large human trials.

Compare this to the evidence base for FDA-approved weight management drugs. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% for placebo [5]. The SURMOUNT-1 trial (N=2,539) found tirzepatide 15 mg achieved 22.5% weight loss at 72 weeks [6]. AOD-9604's evidence is not in the same category.

Dr. Karl Nadolsky, an endocrinologist and obesity medicine specialist, has stated: "Peptides like AOD-9604 have interesting mechanistic data but lack the rigorous Phase III trials and long-term safety data that FDA approval and insurance coverage require. Patients should understand they are using an investigational product."

Safety Considerations for Medicare-Age Patients

Patients on Medicare Advantage are typically 65 and older (or qualify through disability). Age-related factors make safety evaluation especially important for this population.

AOD-9604 has no long-term safety data in humans. The 12-week Phase IIb trial reported adverse events similar to placebo, including headache, upper respiratory infection, and gastrointestinal discomfort [1]. No serious adverse events were attributed to the drug. But 12 weeks in 300 subjects cannot rule out rare or delayed harms.

For older adults, specific concerns include:

• Drug interactions: AOD-9604's interaction profile has not been formally studied. Medicare-age patients take a median of 5 prescription medications according to CDC National Health Statistics, increasing interaction risk [7].
• Injection site reactions: Subcutaneous injections carry a small risk of infection. Patients with diabetes-related skin changes or on anticoagulants need extra caution.
• Renal clearance: Peptide metabolism depends partly on renal function, which declines with age. No dose adjustment guidelines exist because no pharmacokinetic studies have been conducted in elderly populations.
• Cardiovascular unknowns: The American Heart Association recommends that obesity pharmacotherapy in older adults be chosen based on cardiovascular outcomes data [8]. AOD-9604 has none.

The Endocrine Society recommends that older adults considering weight loss pharmacotherapy discuss the risk-benefit ratio with their physician, particularly because unintentional lean mass loss during weight reduction can worsen sarcopenia [9].

Will AOD-9604 Ever Get Insurance Coverage?

Coverage would require one of three developments: FDA approval, a CMS national coverage determination for off-label use, or inclusion in a compendium that CMS recognizes. None of these is currently in progress.

No pharmaceutical company has announced plans to sponsor AOD-9604 through the FDA approval process. The original patents held by Metabolic Pharmaceuticals have expired. Without patent protection, the financial incentive to spend an estimated $1 to $2 billion on Phase III development is absent. This is a common barrier for off-patent peptides.

A second pathway would be CMS issuing a national coverage determination (NCD) for compounded AOD-9604, similar to what exists for certain compounded drugs used in cancer treatment. This requires substantial evidence of medical necessity and typically follows years of clinical use data that AOD-9604 does not have.

The third option, listing in a recognized compendium (such as the American Hospital Formulary Service Drug Information), also requires published evidence of safety and efficacy beyond what currently exists.

Dr. Carolyn Jasik, Chief Medical Officer at Omada Health, has noted: "The bar for Medicare drug coverage is appropriately high. For peptides without Phase III data, the pathway to formulary inclusion remains years away, if it materializes at all."

Patients who want to use AOD-9604 while on Medicare Advantage should plan for ongoing out-of-pocket expenses and should not expect reimbursement through appeals, exceptions, or supplemental coverage riders.

Comparing AOD-9604 to Covered Alternatives

If your primary goal is fat reduction and you need Medicare-covered options, several alternatives carry Part D coverage:

| Drug | FDA-Approved | Medicare Part D | Average Monthly Cost (with coverage) | Key Trial Result | |------|-------------|-----------------|--------------------------------------|-----------------| | Semaglutide 2.4 mg (Wegovy) | Yes | Yes (CV indication) | $25 to $100 copay | 14.9% weight loss at 68 weeks (STEP-1) [5] | | Tirzepatide (Zepbound) | Yes | Varies by plan | $25 to $150 copay | 22.5% weight loss at 72 weeks (SURMOUNT-1) [6] | | Liraglutide 3 mg (Saxenda) | Yes | Limited | $50 to $200 copay | 8.0% weight loss at 56 weeks (SCALE) [10] | | Phentermine-topiramate (Qsymia) | Yes | Yes | $30 to $80 copay | 9.8% weight loss at 56 weeks (CONQUER) [11] | | AOD-9604 | No | No | $150 to $250 cash | 1.3 kg difference vs placebo at 12 weeks [1] |

The efficacy gap is substantial. Patients motivated by cost savings and evidence-based outcomes may find FDA-approved GLP-1 receptor agonists a stronger clinical choice, particularly given the expanded Medicare Part D coverage following the SELECT trial results [3].